Moreover, SPAG6 expression is elevated in de novo AML patients but normalized in those achieving complete remission post-treatment, while correlating with genetic signatures and regulating proliferation and migration of AML cells (Steinbach et al., 2006; Jiang et al., 2019; Mu et al., 2022). The gene discussed is SPAG6; the disease is acute myeloid leukemia.